Long-Term Response to PD-1 and CTLA-4 Blockade in an SCLC Patient with Negative PD-L1 Expression on Biopsy: A Case Report
# Introduction Despite recent advances in the availability of new therapeutic agents, small-cell lung cancer (SCLC) remains an aggressive disease with a poor prognosis. While immune checkpoint inhibition has revolutionized the treatment of non-small cell histologies, results in SCLC have shown over...
Saved in:
| Main Authors: | Marco Cefalì, Francesco Martucci, Patrizia Frösch |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2023-03-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/hbT.OH.2023.15.099 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma
by: Sandip P. Patel, et al.
Published: (2025-01-01) -
CTLA-4 and PD-1 Ligand Gene Expression in Epithelial Thyroid Cancers
by: Chiara Tuccilli, et al.
Published: (2018-01-01) -
Antitumor efficacy of combined CTLA4/PD-1 blockade without intestinal inflammation is achieved by elimination of FcγR interactions
by: Peng Yang, et al.
Published: (2020-10-01) -
PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma
by: Mengjia Song, et al.
Published: (2024-12-01) -
PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies
by: Menglei Jin, et al.
Published: (2024-11-01)